Follow the 넥스트바이오메디컬 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 넥스트바이오메디컬 has published 18 insider filings. Market capitalisation: €330.2bn. The latest transaction was reported on 25 June 2026 (Other). Among the most active insiders: 이은혜. All data is free.
18
Insider Decl.
0
Thresholds
·
13 ops.
Buy Volume
·
1 ops.
Sell Volume
11Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,970 of 26,282 companies
33.8
score / 100
Value
33
Quality
35
FCF yld-0.6%
Earn yld-0.1%
EV/EBITDA·
ROE-0.1%
Gross mgn70%
Net mgn-1.9%
Debt/EBITDA13.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
넥스트바이오메디컬 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biomedical solutions.